Compare BOX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOX | OGN |
|---|---|---|
| Founded | 2005 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 1.5B |
| IPO Year | 2014 | 2020 |
| Metric | BOX | OGN |
|---|---|---|
| Price | $24.18 | $6.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $35.57 | $11.75 |
| AVG Volume (30 Days) | 2.1M | ★ 3.2M |
| Earning Date | 05-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.58 | ★ 0.72 |
| Revenue | $506,142,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $9.41 | $0.42 |
| Revenue Next Year | $8.15 | $1.67 |
| P/E Ratio | $41.41 | ★ $8.83 |
| Revenue Growth | ★ 26.98 | N/A |
| 52 Week Low | $21.61 | $5.69 |
| 52 Week High | $38.80 | $13.25 |
| Indicator | BOX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 39.81 |
| Support Level | $23.29 | N/A |
| Resistance Level | $33.30 | $7.87 |
| Average True Range (ATR) | 0.78 | 0.27 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 63.66 | 41.55 |
Box is a cloud-based content management platform that provides storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file, sync, and share provider. Over time, it built out and acquired workflow and security tools to evolve the pure-play FSS business into a content management business. Most recently, Box has been pursuing an AI-powered, intelligent content management strategy that can allow for metadata extraction and workflow automation.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.